Immunocore Holdings Stock Investor Sentiment

IMCR Stock  USD 32.12  0.30  0.93%   
Slightly above 55% of Immunocore Holdings' investor base is interested to short. The analysis of the overall investor sentiment regarding Immunocore Holdings suggests that many traders are impartial. Immunocore Holdings' investing sentiment overview a quick insight into current market opportunities from investing in Immunocore Holdings. Many technical investors use Immunocore Holdings stock news signals to limit their universe of possible portfolio assets and to time the market correctly.

Panic Vs Confidence

45

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Immunocore Holdings' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Immunocore Holdings.

Immunocore Historical Sentiment

Although Immunocore Holdings' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Immunocore, such as negative comments on social media and news outlets, may cause fear in the market and push Immunocore Holdings' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Immunocore.
  

Immunocore Holdings Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Immunocore Holdings can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Immunocore Holdings Historical Investor Sentiment

Investor biases related to Immunocore Holdings' public news can be used to forecast risks associated with an investment in Immunocore. The trend in average sentiment can be used to explain how an investor holding Immunocore can time the market purely based on public headlines and social activities around Immunocore Holdings. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Immunocore Holdings' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Immunocore Holdings and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Immunocore Holdings news discussions. The higher the estimate score, the more favorable the investor's outlook on Immunocore Holdings.
over three months ago at news.google.com         
With 45 percent stake, Immunocore Holdings plc seems to have captured institutional investors intere...
Google News at Macroaxis
over three months ago at news.google.com         
NEOS Investment Management LLC Invests 262000 in Immunocore Holdings plc - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Immunocores Buy Rating Reaffirmed at HC Wainwright - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Immunocore Sees Large Volume Increase - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Acquisition by Bell John Irving of 14534 shares of Immunocore Holdings at 50.47 subject to Rule 16b-...
Google News at Macroaxis
over three months ago at investing.com         
Immunocore shares hold steady as analyst reaffirms price target
Investing News at Macroaxis
over three months ago at globenewswire.com         
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confi...
Macroaxis News: globenewswire.com
over three months ago at seekingalpha.com         
Immunocore says new data demonstrates Kimmtrak efficacy for uveal melanoma
seekingalpha News
over three months ago at investing.com         
Promising melanoma treatment advances to Phase 3 trial
Investing News at Macroaxis
over three months ago at globenewswire.com         
Immunocore reports updated Phase 1 data of brenetafusp , an ImmTAC bispecific targeting PRAME, in im...
Macroaxis News: globenewswire.com
over three months ago at globenewswire.com         
Immunocore to present at the Jefferies Global Healthcare Conference
Macroaxis News: globenewswire.com
over three months ago at investing.com         
Immunocore gains as Mizuho maintains buy rating
Investing News at Macroaxis
over three months ago at finance.yahoo.com         
Immunocore converts Phase 23 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIM...
Yahoo News
over three months ago at investing.com         
Immunocore advances melanoma trial to phase 3 after FDA talks
Investing News at Macroaxis
over three months ago at www.macroaxis.com         
Discretionary transaction by Baker Bros. Advisors Lp of 1449226 shares of Immunocore Holdings subjec...
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Immunocore Holdings that are available to investors today. That information is available publicly through Immunocore media outlets and privately through word of mouth or via Immunocore internal channels. However, regardless of the origin, that massive amount of Immunocore data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immunocore Holdings news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immunocore Holdings relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immunocore Holdings' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immunocore Holdings alpha.

Immunocore Holdings Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 8676 shares by Herbst Roy Steven of Immunocore Holdings at 58.69 subject to Rule 16b-3
09/17/2024
2
Immunocore Investment Analysts Weekly Ratings Updates
09/18/2024
3
Immunocore Holdings plc Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
10/08/2024
4
ZIVO Bioscience versus Immunocore Head-To-Head Contrast
10/16/2024
5
Discretionary transaction by Baker Bros. Advisors Lp of 674261 shares of Immunocore Holdings subject to Rule 16b-3
10/25/2024
6
Analysts Set Immunocore Holdings plc Price Target at 79.82
10/29/2024
7
Immunocore Upgraded to Buy Heres Why
11/05/2024
8
Wellington Management Group LLPs Strategic Acquisition in Immunocore Holdings PLC
11/08/2024
9
Mizuho downgrades Immunocore stock to Neutral, slashes PT to 38 from 72
11/11/2024
10
T. Rowe Price Investment Management, Inc. Expands Stake in Immunocore Holdings PLC
11/14/2024
11
Is Immunocore Holdings plc the Best Immunotherapy Stock to Buy Now
11/18/2024
12
Immunocore Holdings plc This Small-Cap Stock Is Ready To Explode
11/19/2024

Additional Tools for Immunocore Stock Analysis

When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.